… Arun Sanyal, MD has served as an ad hoc advisor to Roche, Takeda, Merck, Astella, Sanofi,
Exhalenz, and Immuron. He serves as the global PI for trials for Exhalenz and Immuron. …

Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in the
absence of a history of significant alcohol use or other known liver disease. Nonalcoholic …

This guidance provides a data‐supported approach to the diagnostic, therapeutic, and
preventive aspects of nonalcoholic fatty liver disease (NAFLD) care. A “Guidance” document is …

Background Nonalcoholic steatohepatitis is a common liver disease that can progress to
cirrhosis. Currently, there is no established treatment for this disease. Methods We randomly …

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population,
and has no approved drug therapy. Although pharmacotherapies are in development, …

Background and Aims: The pathogenesis of nonalcoholic steatohepatitis (NASH) is unknown.
We tested the hypothesis that NASH is associated with 2 defects: (1) peripheral insulin …

Background The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal …

There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD), paralleling
a worldwide increase in diabetes and metabolic syndrome. NAFLD, a continuum of liver …

These recommendations provide a data-supported approach to the management of patients
with varices and variceal hemorrhage. They are based on the following:(1) formal review …

Guidelines; 1 (3) guideline policies of the three societies approving this document; and (4) the
experience of the authors and independent reviewers with regards to NAFLD. Intended for …